Current Edition

antibodies

GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K

GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer, today announces that two peer-reviewed articles have been published …

Continue Reading →